Short answer
Atrium Therapeutics, Inc. (RNA) filed an 8-K current report with the SEC on October 8, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities). $50 million gross PIPE financing, strengthening Atrium’s cash position before placement fees and offering expenses.
Atrium Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $50 million gross PIPE financing, strengthening Atrium’s cash position before placement fees and offering expenses
- Issuance of 5,170,384 common shares plus pre-funded warrants for 1,134,930 shares, creating substantial dilution risk
- Shares priced at $7.93, with warrants priced at $7.929 and a nominal $0.001 exercise price
- Closing expected October 9, 2026, subject to customary conditions
- Resale registration required within 50 days of closing, potentially increasing future trading supply and selling pressure
Item 3.02 · Unregistered Sales of Equity Securities
- Unregistered financing under Securities Act Section 4(a)(2), avoiding public-offering registration requirements
- Shares, pre-funded warrants and warrant shares issued or sold to investors
- Offering terms, proceeds and potential dilution covered by Item 1.01, requiring review of that section for investor impact
Item 8.01 · Other Events
- Planned offering targeting approximately $50 million gross proceeds before fees and expenses
- Funding supports two lead candidates, research programs, working capital and general corporate purposes
- Cash resources expected to fund operations through 2028, extending runway and reducing near-term financing risk
- Post-offering shares outstanding expected at 22,276,027, indicating dilution for existing shareholders
- Closing remains conditional, creating execution risk around proceeds and projected cash runway
Item EX-99.1 · Exhibit EX-99.1
- $50 million private placement, priced at-the-market at $7.93 per share
- Issuance of 5,170,384 shares plus pre-funded warrants for 1,134,930 shares, creating substantial dilution
- Proceeds support lead candidates, research, working capital and corporate purposes
- Cash, investments and financing expected to fund operations through 2028, extending near-term financing needs
- Closing expected October 9, 2026, subject to customary conditions; resale registration required for investors' securities
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Atrium Therapeutics, Inc. 8-K filings
Get the next RNA 8-K as it lands
Follow RNA for push alerts, or ask the research agent what this filing means.